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Abstract
The innate immune kinase TBK1 initiates inflammatory responses
to combat infectious pathogens by driving production of type I
interferons. TBK1 also controls metabolic processes and promotes
oncogene-induced cell proliferation and survival. Here, we demon-
strate that TBK1 activates mTOR complex 1 (mTORC1) directly. In
cultured cells, TBK1 associates with and activates mTORC1 through
site-specific mTOR phosphorylation (on S2159) in response to
certain growth factor receptors (i.e., EGF-receptor but not insulin
receptor) and pathogen recognition receptors (PRRs) (i.e., TLR3;
TLR4), revealing a stimulus-selective role for TBK1 in mTORC1
regulation. By studying cultured macrophages and those isolated
from genome edited mTOR S2159A knock-in mice, we show that
mTOR S2159 phosphorylation promotes mTORC1 signaling, IRF3
nuclear translocation, and IFN-b production. These data demon-
strate a direct mechanistic link between TBK1 and mTORC1 func-
tion as well as physiologic significance of the TBK1-mTORC1 axis in
control of innate immune function. These data unveil TBK1 as a
direct mTORC1 activator and suggest unanticipated roles for
mTORC1 downstream of TBK1 in control of innate immunity,
tumorigenesis, and disorders linked to chronic inflammation.
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Introduction
TANK-binding kinase 1 (TBK1; aka NAK or T2K) and IKKe (IkB
kinase e) (aka IKKi, for “inducible”) represent non-canonical
IKK-related innate immune kinases that mediate production of
interferons and interferon-stimulated genes (ISGs) downstream of
Toll-like receptors (TLRs), which function as pathogen recognition
receptors (PRRs; Hacker & Karin, 2006; Clement et al, 2008;
Mogensen, 2009). Upon PRR activation by pathogen-associated
molecular patterns (PAMPs), TLR signaling initiates host defense
responses that eliminate pathogenic microbes (Mogensen, 2009;
O’Neill et al, 2013). TANK-binding kinase 1 expression is ubiquitous
while IKKe expression is tissue-restricted but inducible (Hacker &
Karin, 2006; Clement et al, 2008). While the canonical IKKs (i.e.,
IKKa; IKKb) promote NF-jB-mediated pro-inflammatory gene
expression, TBK1 and IKKe phosphorylate the transcription factors
IRF3 and IRF7 and promote their dimerization, nuclear transloca-
tion, and transcriptional activation, resulting in transcriptional
induction of type I interferons (e.g., IFN-a; IFN-b; Fitzgerald et al,
2003; Hacker & Karin, 2006; Karin, 2009; Mogensen, 2009). TLR3
and TLR4 signal through the adaptor TRIF to activate TBK1 by an
incompletely defined mechanism that involves TBK1 dimerization,
K63-linked polyubiquitination, and activation loop phosphorylation
by an unknown kinase and/or by auto-phosphorylation (Hacker &
Karin, 2006; Mogensen, 2009; Ma et al, 2012; Tu et al, 2013). In
addition to well-defined roles in innate immunity, emerging work
suggests that TBK1 and IKKe contribute to various pathological
conditions including autoimmune diseases, obesity-associated
metabolic disorders, and cancer (Chiang et al, 2009; Grivennikov
et al, 2010; Shen & Hahn, 2011; Yu et al, 2012; Reilly et al, 2013).
In oncogenic KRAS transformed cells, TBK1 is required for anchor-
age-independent cell proliferation and survival, as well as the
growth of tumor explants in vivo (Chien et al, 2006; Clement et al,
2008; Barbie et al, 2009; Ou et al, 2011; Xie et al, 2011). In addition,
IKKe contributes to cell transformation and exhibits amplification in
breast cancer cells (Boehm et al, 2007).
Mechanistic target of rapamycin (mTOR), an evolutionarily
conserved serine/threonine protein kinase, integrates diverse
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environmental signals and translates these cues into appropriate
cellular responses (Huang & Fingar, 2014; Dibble & Cantley,
2015; Saxton & Sabatini, 2017). Mechanistic target of rapamycin
promotes cell growth, proliferation, and survival and modulates
immune function and cell metabolism. Consequently, aberrant
mTOR signaling has been linked to myriad pathologic states
including cancer and obesity-linked diabetes (Zoncu et al, 2011;
Laplante & Sabatini, 2012; Cornu et al, 2013). Despite the clear
physiologic and therapeutic importance of mTOR, the biochemi-
cal pathways and molecular mechanisms that regulate mTOR
function in response to diverse cellular cues and physiologic
contexts remain incompletely deciphered. mTOR forms the cata-
lytic core of two functionally distinct complexes defined by
distinct partner proteins and sensitivities to the allosteric mTOR
inhibitor rapamycin. The mTOR interacting protein raptor defines
mTOR complex 1 (mTORC1; sensitive to acute rapamycin) while
rictor defines mTOR complex 2 (mTORC2; insensitive to acute
rapamycin; Hara et al, 2002; Kim et al, 2002; Sarbassov et al,
2004; Thoreen & Sabatini, 2009; Laplante & Sabatini, 2012;
Cornu et al, 2013). Well-described substrates of mTORC1 include
S6K1 (ribosomal protein S6 kinase 1) and the translational
repressor 4EBP1 (eIF4E-binding protein 1; Jacinto & Lorberg,
2008; Magnuson et al, 2012; Huang & Fingar, 2014). Anabolic
cellular signals such as growth factors (i.e., insulin; EGF) and
nutrients (i.e., amino acids, glucose) promote mTORC1 signaling
to increase protein, lipid, and nucleotide synthesis (Ma & Blenis,
2009; Dibble & Manning, 2013; Howell et al, 2013; Ricoult &
Manning, 2013). While the regulation of mTORC2 remains less
defined, mTORC2 phosphorylates Akt to modulate cell metabo-
lism and promote cell survival (Sarbassov et al, 2005; Alessi
et al, 2009).
Here, we demonstrate that the innate immune kinase TBK1
associates with and promotes mTOR complex 1 (mTORC1) cata-
lytic activity and downstream signaling directly through
site-specific mTOR phosphorylation, thus unveiling new crosstalk
between these important signaling systems. Although not mecha-
nistically defined here, our data also indicate that TBK1
promotes mTORC2 signaling, which supports published work
(Ou et al, 2011; Xie et al, 2011). EGF- but not insulin-receptor-
mediated mTORC1 signaling requires TBK1 and mTOR S2159
phosphorylation, indicating a stimulus-selective role for TBK1 in
mTORC1 regulation by growth factors. During innate immune
signaling, TRL3- and TLR4-induced mTORC1 signaling also
requires TBK1 and mTOR S2159 phosphorylation. By studying
IFN-b production in cultured and primary macrophages, we
demonstrate that the TBK1-mTORC1 axis controls physiologically
relevant innate immune function. mTORC1 inhibition with
rapamycin suppresses TLR3-induced IFN-b production by
blunting the translocation of IRF3 from the cytosol to nucleus.
Moreover, primary macrophages isolated from genome edited
mice bearing a germline mTOR S2159A knock-in allele show
impaired mTORC1 signaling, IRF3 translocation, and IFN-b
production. Taken together, these data unveil TBK1 as a direct
activator of mTORC1 and suggest roles for mTORC1 downstream
of TBK1, which may improve our understanding of innate
immunity as well as disorders linked to chronic low-grade
inflammation such as cancer, diabetes, and autoimmune
diseases.
Results
TBK1 interacts with and phosphorylates mTOR within mTORC1
In previous work, we demonstrated that dual mTOR phosphoryla-
tion on S2159 and T2164 promotes mTOR complex 1 (mTORC1)
signaling and mTORC1-mediated cell growth (Ekim et al, 2011). To
identify upstream mTOR kinases for these sites, we performed
in vitro kinome screens. Roughly 300 recombinant active kinases
were tested for their ability to phosphorylate recombinant GST-
mTOR (32 amino acids; 2,144–2,175) in a site-specific manner.
Mechanistic target of rapamycin phosphorylation was measured by
dot-blot analysis with mTOR phospho-specific antibodies (Ekim
et al, 2011; Fig EV1A) and by incorporation of [32P] on wild-type
GST-mTOR but not on phospho-deficient Ala substitution mutant
(Fig EV1B). TBK1 and IKKe provided the strongest site-specific
mTOR S2159 phosphorylation. Indeed, the mTOR amino acid
sequence surrounding S2159 fits consensus motifs found in defined
TBK1 substrates (i.e., IRF3; IRF7; optineurin; suppressor of IKKe
[SIKE]; Wild et al, 2011; Marion et al, 2013) and bears similarity to
an IKKe consensus phosphorylation motif (Fig 1A; Peters et al,
2000; Hutti et al, 2009). At this time, the upstream mTOR T2164
kinase remains unknown. We validated these screens with conven-
tional in vitro kinase assays. Recombinant active TBK1 and IKKe
each phosphorylated GST-mTOR S2159 in vitro in a manner sensi-
tive to the TBK1/IKKe pharmacologic inhibitors amlexanox, BX-795
and MRT-67307 (a derivative of BX-795) (Clark et al, 2009, 2011;
Reilly et al, 2013; Fig 1B). Recombinant active TBK1 and IKKe also
phosphorylated full-length wild-type but not S2159A Myc-mTOR
directly in vitro (Fig 1C). When immunoprecipitated from HEK293
cells, transfected wild-type (WT) but not kinase dead (KD) Flag-
TBK1 and Flag-IKKe phosphorylated GST-mTOR S2159 in vitro
(Fig EV1C). These data confirm the site specificity of the P-S2159
antibody (demonstrated by us previously; Ekim et al, 2011) and
show that TBK1 and IKKe phosphorylate full-length mTOR as well
as a truncated mTOR fragment.
We next investigated whether TBK1 and IKKe increase mTOR
S2159 phosphorylation in intact cells. Overexpression of Flag-TBK1
in HEK293 cells expressing TLR3 increased P-S2159 on Myc-mTOR,
while treatment with poly(I:C) (polyinosinic: polycytidylic acid), a
double-stranded RNA mimetic that binds to and activates TLR3,
increased mTOR P-S2159 further (Fig 1D). Overexpression of wild-
type but not kinase-dead Flag-TBK1 and Flag-IKKe in HEK293 cells
increased mTOR S2159 phosphorylation on wild-type but not
S2159A Myc-mTOR in a manner sensitive to BX-795 (Fig EV1D and
E). Treatment of HEK293 cells expressing endogenous TBK1 with
BX-795 reduced mTOR P-S2159 (Fig EV1F). These data indicate that
TBK1 promotes mTOR S2159 phosphorylation in intact cells. Flag-
TBK1 and Flag-IKKe overexpression also increased mTOR S2159
phosphorylation on HA-raptor-associated Myc-mTOR (Fig 1E), indi-
cating that TBK1/IKKe increase mTOR phosphorylation within
mTORC1. Flag-TBK1 and Flag-IKKe interacted with both endogenous
raptor (Fig 1F) and exogenously expressed HA-raptor (Fig EV1G and
H) by co-immunoprecipitation assay. Importantly, immortalized
TBK1/ MEFs exhibited reduced mTOR P-S2159 relative to litter-
mate-matched TBK1+/+ MEFs (Fig 1G; see also Fig 2H). Taken
together, these data suggest that these innate immune kinases inter-
act with and phosphorylate mTOR and within mTORC1.
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We next analyzed TBK1/IKKe-mediated mTOR phosphorylation
in cultured and primary macrophages, cells in which TLR3 and
TLR4 engagement with microbial PAMPs activates TBK1 and IKKe
during an innate immune response. Activation of TBK1/IKKe in
cultured RAW264.7 macrophages upon treatment with poly(I:C)
and LPS (lysophosphatidic acid) (a bacterial cell wall component
that binds to and activates TLR4) increased mTOR P-S2159 in a
BX-795 sensitive manner (Fig 1H). Similarly, TBK1/IKKe activation
in primary bone marrow-derived macrophages (BMDMs) with
poly(I:C) and LPS increased mTOR P-S2159 (Fig 1I). Importantly,
we confirmed activation of TBK1 and IKKe by measuring phospho-
rylation on their activation loop sites (S172) in cultured and primary
macrophages. To extend these results to an in vivo setting, we
injected mice acutely (2 h) with LPS. LPS increased mTOR S2159
phosphorylation in spleen tissue, a source of abundant monocytes
(Fig 1J). As expected, LPS activated TBK1 in spleen, as determined
by increased phosphorylation of TBK1 P-S172. Moreover, LPS
increased mTORC1 signaling (as measured by the phosphorylation
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of the mTORC1 substrate S6K1 on T389; Fig 1J), consistent with an
earlier finding that LPS administered to mice in vivo increased
mTORC1 signaling in several tissues in a rapamycin-sensitive
manner (e.g., liver; lung; kidney; Lee et al, 2010). We also found
that LPS administered in vivo increased mTORC2 signaling (as
measured by the phosphorylation of the mTORC2 substrate Akt (on
S473). These data demonstrate that TLR4 signaling in vivo activates
TBK1 and promotes mTOR S2159 phosphorylation, events that
correlate with increased mTORC1 and mTORC2 signaling. Taken
together, the data demonstrate that TBK1/IKKe associate with and
phosphorylate mTOR within mTORC1. Whether TBK1/IKKe phos-
phorylates other sites on mTOR or mTORC1 components in addition
to S2159 remains an open question.
TBK1 promotes growth factor-induced mTORC1 signaling in a
stimulus-selective manner
We next focused on the role of TBK1 in control of growth factor-
induced mTORC1 signaling by studying TBK1+/+ and TBK1/
MEFs. An EGF time course (1–60 min) revealed substantially
stronger EGF-stimulated mTORC1 signaling in TBK1+/+ wild-type
MEFs relative to TBK1/ null MEFs at all time points (Fig 2A; see
also Fig 2D). These data indicate that TBK1 contributes to EGF-
receptor signaling to mTORC1. As immortalized MEFs can possess
clonal differences due to divergence in culture, we confirmed that
re-introduction of wild-type Flag-TBK1 into TBK1/ MEFs rescued
EGF-induced S6K1 T389 phosphorylation (Fig 2B). Re-introduction
of kinase-dead Flag-TBK1 rescued mTORC1 signaling modestly,
suggesting that while TBK1 kinase activity is important for mTORC1
signaling, TBK1 may also provide kinase-independent scaffolding
function (Fig 2B). Importantly, we also confirmed that EGF-receptor
signaling remains intact in these immortalized TBK1/ MEFs. EGF-
stimulated phosphorylation of EGF-receptor (Y1173, an auto-
phosphorylation site), P-STAT3 (Y705), and MAPK (T202/Y204)
remained intact in TBK1 null MEFs relative to wild-type MEFs
(Fig 2C). We noted that TBK1/ MEFs exhibit increased basal
levels of P-STAT3-Y705 relative to TBK1+/+ MEFs. While we do not
know the reason for this phenomenon at this time, we speculate
that it may result from reduced TBK1- or mTORC1-mediated nega-
tive feedback in TBK1/ MEFs, leading to elevated P-STAT3.
Consistent with a role for TBK1 in EGF-stimulated mTORC1 signal-
ing, pre-treatment of TBK1+/+ MEFs with the TBK1/IKKe inhibitor
amlexanox reduced EGF-stimulated S6K1 phosphorylation (Fig 2D);
as expected, the mTOR catalytic inhibitor Ku-0063794 ablated S6K1
phosphorylation. Thus, genetic or pharmacologic inactivation of
TBK1 reduces EGF-stimulated mTORC1 signaling. It is important to
note that we avoided use of the better known TBK1/IKKe inhibitors
BX-795 and MRT-67307 (Clark et al, 2009, 2011) for analysis of
mTORC1 signaling due to documented TBK1 independent inhibitory
effects on regulatory mTORC1-S6K1 pathway components. BX-795
was originally developed as an inhibitor of PDK1, the kinase that
phosphorylates S6K1 on its activation loop site (T229). As PDK1-
mediated phosphorylation of T229 was reported to promote
mTORC1-mediated phosphorylation of S6K1 T389 (Keshwani et al,
2011), inhibition of PDK1 with BX-795 (or its derivative MRT-
67037) could reduce mTORC1-mediated S6K1 P-T389 through a
TBK1 independent mechanism. To avoid this complication, we
employed the more recently identified TBK1/IKKe inhibitor amlex-
anox (Reilly et al, 2013), as no inhibitory effects on mTORC1-S6K1
pathway components have been reported.
Unlike EGF-induced mTORC1 signaling, insulin-induced
mTORC1 signaling was similar in TBK1+/+ and TBK1/ MEFs,
and amlexanox had no inhibitory effect on S6K1 T389 phosphoryla-
tion (Fig 2E). These data indicate that TBK1 is not required for
insulin-receptor signaling to mTORC1. We also compared insulin-
and EGF-stimulated mTORC1 signaling side by side and included
analysis of 4EBP1, another well-studied mTORC1 substrate. Relative
to TBK1+/+ MEFs, TBK1/ MEFs exhibited reduced mTORC1
dependent S6K1 (T389) and 4EBP1 (T70; S65; T46) phosphorylation
in response to EGF but not insulin (Fig 2F). Similar to MEFs,
◀ Figure 1. TBK1 interacts with and phosphorylates mTOR within mTORC1.A The mTOR S2159 sequence fits TBK1 and IKKe consensus phosphorylation motifs.
B TBK1/IKKe phosphorylate mTOR S2159 directly in vitro. In vitro kinase (IVK) assays with recombinant (re) active TBK1 or IKKe [50 ng] (Invitrogen) and recombinant
GST-mTOR substrate [200 ng] for 30 min at 30°C. Reactions were pre-incubated on ice 30 min with amlexanox [500, 250 or 50 lM], BX-795 [10 lM] or MRT-67307
[10 lM] and immunoblotted (IB) as indicated.
C TBK1/IKKe phosphorylate full-length mTOR on S2159. Myc-mTOR wild type (WT) and S2159A were immunoprecipitated (IP) from transfected HEK293 cells and
incubated with re-TBK1 or re-IKKe. IVK assays were performed as above and immunoblotted (IB) as indicated.
D TBK1 overexpression increases mTOR P-S2159, and poly(I:C) boosts this phosphorylation further. HEK293-TLR3 cells were co-transfected with Flag-TBK1 and
Myc-mTOR. Cells were serum-starved (20 h) and stimulated /+ poly(I:C) [50 lg/ml] (2 h). Myc-mTOR immunoprecipitates were immunoblotted (IB) as indicated.
E TBK1 and IKKe overexpression increases mTOR P-S2159 within mTORC1. HEK293-TLR3 cells were co-transfected with Flag-TBK1 or Flag-IKKe, Myc-mTOR, and
HA-raptor. HA-raptor immunoprecipitates and whole-cell lysates (WCL) were immunoblotted (IB) as indicated.
F Flag-TBK1 and Flag-IKKe co-immunoprecipitate with endogenous mTORC1. HEK293T cells were transfected with Flag-TBK1 or Flag-IKKe wild type (+) or kinase dead
(KD). Endogenous raptor immunoprecipitates and WCL were immunoblotted (IB) as indicated.
G mTOR is phosphorylated on S2159 in wild type but not TBK1 null MEFs. TBK1+/+ and TBK1/ MEFs were serum-starved (20 h) and stimulated  EGF [25 ng/ml].
WCL was immunoblotted (IB) as indicated. The arrow indicates mTOR phosphorylated on S2159.
H The TBK1- and IKKe-activating agonists poly(I:C) and LPS increase mTOR P-S2159 in a BX-795-sensitive manner in cultured macrophages. RAW264.7 macrophages
were pre-treated with BX-795 [10 lM] (2 h) and stimulated /+ poly(I:C) [30 lg/ml] or LPS [100 ng/ml] (60 min).
I Poly(I:C) and LPS increase mTOR P-S2159 in primary bone marrow-derived macrophages (BMDMs). BMDMs were stimulated /+ poly(I:C) [30 lg/ml] or LPS [100 ng/
ml] (60 min).
J LPS increases mTOR P-S2159 in vivo. Mice (C57BL6, 6 weeks old) were injected intraperitoneally with PBS or LPS [1 mg/kg BW] (2 h). mTOR was immunoprecipitated
from spleen tissue, and IPs and WCL were immunoblotted as indicated. The graph depicts levels of mTOR P-S2159 relative to total mTOR in spleen tissue /+ LPS.
n = 8 from 3 independent experiments  SD. *P = 0.004 relative to PBS-treated control mice by paired t-test (two-tailed).
Source data are available online for this figure.
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amlexanox reduced EGF- but not insulin-stimulated mTORC1 signal-
ing in HEK293 cells (Fig 2G). To begin to understand why the EGF
but not the insulin pathway requires TBK1 to promote mTORC1
signaling, we examined mTOR S2159 phosphorylation in response
to EGF vs. insulin. We found that EGF increases mTOR P-S2159 to a
greater extent than insulin (Fig 2H), suggesting that EGF but not
A
D
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B C
Figure 2. TBK1 promotes growth factor-induced mTORC1 signaling in a stimulus-selective manner.
A EGF increases mTORC1 signaling in a TBK1-dependent manner. TBK1+/+ and TBK1/ MEFs were serum-starved (20 h), pre-treated with Ku-0063794 [1 lM] (30 min),
and stimulated /+ EGF [25 ng/ml] (0–60 min). Whole-cell lysates (WCL) were immunoblotted (IB) as indicated.
B Ectopic expression of TBK1 rescues mTORC1 signaling in TBK1/ MEFs. TBK1/ MEFs were transiently transfected with vector control (V), wild type (WT), or kinase-
dead (KD) Flag-TBK1, serum-starved (20 h), and analyzed as above.
C EGF-receptor signaling remains intact in TBK1/ MEFs. TBK1+/+ and TBK1/ MEFs were serum-starved (20 h) and stimulated /+ EGF [25 ng/ml] (0, 5, or 15 min).
D TBK1 is required for EGF-stimulated mTORC1 and mTORC2 signaling. TBK1+/+ and TBK1/ MEFs were stimulated with EGF as in (A).
E TBK1 is not required for insulin-stimulated mTORC1 signaling. TBK1+/+ and TBK1/ MEFs were stimulated with insulin as in (C).
F Side-by-side comparison of EGF- vs. insulin-stimulated mTORC1 and mTORC2 signaling in TBK1+/+ vs. TBK1/ MEFs. MEFs were treated as in (C).
G Pharmacologic TBK1 inhibition reduces EGF-induced mTORC1 signaling. HEK293 cells were serum-starved (20 h), pre-treated with Ku-0063794 [1 lM] (30 min) or
amlexanox [50 lM] (2 h), and stimulated /+ EGF [25 ng/ml] (30 min) or insulin (INS) [100 nM] (30 min).
H EGF but not insulin increases mTOR P-S2159. TBK1+/+ vs. TBK1/ MEFs: MEFs were treated as in (C). The arrow indicates mTOR phosphorylated on S2159.
Source data are available online for this figure.
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insulin signaling either activates TBK1 or alternately primes mTOR
for TBK1-mediated phosphorylation. Previous work demonstrated
that cellular EGF treatment increased the kinase activity of immuno-
precipitated TBK1 toward His-Akt1 substrate in vitro (Ou et al,
2011), suggesting that EGF increases TBK1 intrinsic catalytic activ-
ity. Unexpectedly, EGF stimulation of MEFs and HEK293-TLR3 cells
failed to increase TBK1 phosphorylation on the activation loop site
(S172) while increasing mTORC1 signaling (Fig EV2A and B). As
expected, innate immune agonists (i.e., LPS; poly(I:C)) increased P-
TBK1-S172 and mTORC1 signaling concomitantly (Fig EV2A and B).
These data require further investigation but suggest that either
TBK1 activation loop site phosphorylation does not represent an
accurate readout of TBK1 kinase activity in response to EGF or that
EGF-receptor signaling does not activate TBK1. Finally, we asked if
TBK1 plays a role in amino acid activated mTORC1 signaling. We
found that acute amino acid stimulation of amino acid-deprived
cells increases P-S6K1 T389 similarly in TBK1+/+ and TBK1/
MEFs, indicating that TBK1 is not required for activation of
mTORC1 by amino acids (Fig EV2C). As a final cautionary note, we
noted that overexpression of Flag-TBK1 suppressed mTORC1 signal-
ing (Fig EV2D), likely due to inappropriate interaction of overex-
pressed TBK1 with mTORC1 or regulatory factors. Taken together,
the data indicate that TBK1 contributes in a stimulus-selective
manner to activation of mTORC1 signaling, with TBK1 playing a
dominant role in the EGF- but not insulin- or amino acid-mediated
activation of mTORC1.
We noted that phosphorylation of Akt S473, a site phosphory-
lated directly by mTORC2, was reduced in TBK1/ MEFs relative
to TBK1+/+ MEFs in response to EGF (Fig 2A, D and F), consistent
with published work (Ou et al, 2011; Xie et al, 2011). As expected,
the mTOR inhibitor Ku-0063794 suppressed Akt S473 phosphoryla-
tion strongly (Fig 2A, D and F; Sarbassov et al, 2005). Collectively,
the data indicate that the TBK1-mTOR axis promotes both mTORC1
and mTORC2 signaling, with TBK1 positioned as a critical effector
of EGF-receptor signaling. As Akt positively regulates mTORC1
through inhibitory phosphorylation of Tsc2 (Inoki et al, 2002;
Manning et al, 2002) and PRAS40 (van der Haar et al, 2007; Sancak
et al, 2007), we sought to exclude the possibility that reduced
mTORC1 signaling in TBK1/ MEFs results indirectly from reduced
Akt S473 phosphorylation and activity. PDK1-mediated phosphory-
lation of Akt on its activation loop site (T308) is essential for its
catalytic activity (Pearce et al, 2010) whereas mTORC2-mediated
phosphorylation of Akt on its hydrophobic motif site (S473) boosts
catalytic activity and directs Akt substrate preference toward certain
substrates (i.e., Foxo3) but not others (i.e., PRAS40; GSK3; Tsc2;
Guertin et al, 2006; Jacinto et al, 2006; Pearce et al, 2010).
Published work shows that cells lacking rictor, an mTOR partner
critical for mTORC2 function, maintain mTORC1 signaling despite
extremely low Akt S473 phosphorylation (Sarbassov et al, 2005;
Guertin et al, 2006; Jacinto et al, 2006). By studying rictor/ MEFs
reconstituted with either vector control or HA-rictor, we confirmed
that EGF-stimulated S6K1 T389 phosphorylation remains intact in
cells with reduced Akt S473 phosphorylation (Fig 3A). Despite
modestly reduced Akt T308 phosphorylation, often observed in cells
with reduced Akt S473 phosphorylation (Sarbassov et al, 2005),
phosphorylation of the Akt substrates PRAS40, GSK3, and Tsc2
remained intact (Fig 3A). Taken together, these data indicate that
Akt retains significant catalytic activity in cells with an impaired
mTORC2-Akt P-S473 axis (Fig 3A). Moreover, knockdown of TBK1
using shRNA reduced EGF-stimulated S6K1 T389 phosphorylation
in rictor/ MEFs (Fig 3B), verifying an important role of TBK1 in
mTORC1 activation in cells that lack mTORC2 function. Collec-
tively, the data support a model in which TBK1 promotes mTORC1
signaling by a direct mechanism rather than an indirect mechanism
involving modulation of Akt S473 phosphorylation.
In response to EGF-receptor activation, TBK1 promotes mTORC1
signaling and catalytic activity in a manner that depends on
mTOR S2159 phosphorylation
To determine whether EGF-stimulated mTORC1 signaling
requires phosphorylation of mTOR on the TBK1 site (S2159), we
A B
Figure 3. TBK1 promotes mTORC1 signaling independently of mTORC2-
dependent Akt S473 phosphorylation.
A mTORC1 signaling remains intact in MEFs lacking mTORC2 function.
Rictor/ MEFs stably expressing vector control (V) or rescued stably with
HA-rictor were serum-starved (20 h), pre-treated with Ku-0063794 [1 lM]
(30 min), and stimulated /+ epidermal growth factor (EGF) [25 ng/ml]
(30 min). Whole-cell lysates (WCL) were immunoblotted as indicated. The
arrow indicates mTOR auto-phosphorylated on S2481.
B TBK1 is required for mTORC1 signaling in MEFs with reduced Akt S473
phosphorylation. TBK1 expression was reduced using lentivirally delivered
TBK1 shRNA in Rictor/ MEFs stably expressing vector control (V). Cells
were EGF stimulated as above, except Torin1 [100 nM] (T) was used to
inhibit mTOR.
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performed a chemical mTOR knockout-rescue experiment using a
rapamycin-resistant (RR) allele of mTOR (S2035I) that cannot bind
rapamycin and its obligate partner FKBP12 (Stan et al, 1994; Chen
et al, 1995). Expression of RR-mTOR enables the signaling capacity
of mTORC1 containing exogenously expressed mutant mTOR alle-
les to be studied in the absence of endogenous mTORC1 function
upon chemical knockout with rapamycin (Brown et al, 1995; Hara
et al, 1997). As expected, rapamycin abrogated HA-S6K1 phospho-
rylation in HEK293 cells expressing wild-type (WT) AU1-mTOR,
and expression of rapamycin-resistant (RR) AU1-mTOR rescued
HA-S6K1 T389 phosphorylation during rapamycin treatment
(Fig 4A). In response to EGF, HA-S6K1 phosphorylation was
reduced in cells expressing RR-mTOR with a S2159A substitution
relative to RR-mTOR with a wild-type backbone (Fig 4A). More-
over, substitution of a phospho-mimetic Asp (D) residue at S2159
within RR-mTOR (S2159D) rescued HA-S6K1 phosphorylation rela-
tive to RR-mTOR S2159A. These data indicate that mTOR S2159
phosphorylation is required for EGF-stimulated mTORC1 signaling,
at least in part.
We next investigated the molecular mechanism by which TBK1
promotes EGF-induced mTORC1 signaling. EGF-stimulated mTOR
S2481 auto-phosphorylation was reduced in TBK1/ MEFs
compared to TBK1+/+ MEFs (Fig 4B; also, see Fig 2F). It is impor-
tant to note that mTOR S2481 auto-phosphorylation correlates with
active mTORC1 and mTORC2 signaling and thus represents a simple
method to monitor overall mTOR and complex specific catalytic
activity in intact cells (Soliman et al, 2010). Time course analysis
revealed that EGF increased mTOR S2481 auto-phosphorylation
from 5 to 60 min more strongly in TBK1+/+ than TBK1/ MEFs
(Fig 4C). As before, S6K1 T389 and Akt S473 phosphorylation were
significantly reduced in TBK1/ MEFs relative to TBK1+/+ MEFs
(Fig EV3A). To determine whether TBK1 promotes mTORC1-
specific catalytic activity, we measured raptor-associated mTOR
S2481 auto-phosphorylation. EGF increased mTORC1 catalytic activ-
ity in TBK1+/+ but not TBK1/ MEFs in an mTOR-dependent
manner (Fig 4D). Moreover, EGF-stimulated mTOR S2481 auto-
phosphorylation was reduced on Myc-mTOR S2159A and kinase-
dead alleles relative to wild type (Fig 4E), indicating that mTOR
S2159 phosphorylation contributes to mTOR catalytic activity. These
data indicate that TBK1 increases mTORC1 catalytic activity to
promote mTORC1 downstream signaling. By pharmacologically
inhibiting class I PI3Ka (with BYL-719), Akt (with MK-2206), and
MAPK (with CI-1040; Fig EV3B and C), we demonstrated that the
EGF-receptor signals through at least three parallel pathways that
converge on mTORC1- PI3Ka/Akt, MAPK, and here TBK1 (Fig 4F).
In response to TLR3 and TLR4 activation, TBK1 promotes mTORC1
signaling and catalytic activity in a manner dependent on mTOR
S2159 phosphorylation
To examine mTORC1 regulation by TBK1 within innate immune
signaling networks, we stimulated RAW264.7 macrophages with the
TLR3 agonist poly(I:C) and the TLR4 agonist LPS. Both TLR agonists
increased phosphorylation of the mTORC1 targets S6K1 (T389) and
4EBP1 (S65; T46; Fig 5A), consistent with an earlier report (Schmitz
et al, 2008), in a manner sensitive to the TBK1 inhibitor amlexanox
and the mTOR inhibitor Ku-0063794. Amlexanox also blunted poly
(I:C)- and LPS-induced Akt S473 phosphorylation, indicating
suppression of mTORC2 signaling. As expected, poly(I:C) and LPS
activated TBK1, as monitored by increased phosphorylation of
TBK1 on its activation loop site (S172) and amlexanox-sensitive
phosphorylation of the TBK1 substrate IRF3 (S396), the transcrip-
tion factor that drives production of type I interferons (Fitzgerald
et al, 2003) (Fig 5A). To confirm that amlexanox reduces mTORC1
signaling through inhibition of TBK1 and not due to an off-target
effect, we employed RNAi approaches to knockdown TBK1 expres-
sion in RAW264.7 macrophages (note that we found it difficult to
knockdown IKKe). Knockdown of TBK1 with lentivirally delivered
shRNA reduced both poly(I:C)- and LPS-induced S6K1 T389 phos-
phorylation (Fig 5B) as did TBK1 knockdown with siRNA
(Fig EV4A). Similar to RAW264.7 macrophages, amlexanox reduced
mTORC1 signaling in primary bone marrow-derived macrophages
(BMDMs) in response to poly(I:C) and LPS (Fig 5C). In HEK293-
TLR3 cells stimulated with poly(I:C), amlexanox reduced both
mTORC1 and mTORC2 signaling (Fig 5D). Lastly, LPS increased
mTORC1 signaling in TBK1+/+ but not TBK1/ MEFs in an amlex-
anox-sensitive manner (Fig 5E). Taken together, these data indicate
that TLR3- and TLR4-mediated activation of TBK1 promotes
mTORC1 and mTORC2 signaling in several cell types.
To test a requirement for site-specific mTOR S2159 phosphoryla-
tion in TLR3- and TLR4- induced mTORC1 signaling, we again
performed mTOR chemical knockout-rescue experiments utilizing
rapamycin-resistant (RR) mTOR alleles. Phosphorylation of HA-
S6K1 in RAW264.7 macrophages expressing RR-mTOR-S2159A was
reduced relative to those expressing RR-mTOR in response to poly(I:
C) (Fig 6A) and LPS (Fig 6B). These data demonstrate that mTOR
S2159 phosphorylation promotes TLR3- and TLR4-stimulated
mTORC1 signaling, at least in part. We next asked whether TLR3
and TLR4 signaling increases mTORC1 catalytic activity in a TBK1-
dependent manner. Amlexanox reduced raptor-associated mTOR
S2481 auto-phosphorylation in response to poly(I:C) and LPS
(Fig 6C). Amlexanox also reduced S2481 auto-phosphorylation on
total mTOR in response to poly(I:C) and LPS in RAW264.7 macro-
phages (see Fig 5A) and primary BMDMs (see Fig 5C), as did
BX-795 and MRT-67037 (Fig EV4B). These data demonstrate that
TBK1 is required for mTORC1 catalytic activity in response to TLR3
and TLR4 signaling. By pharmacologically inhibiting class I PI3Ka
(with BYL-719), Akt (with MK-2206), and TBK1 (with amlexanox),
we found that TLR3 and TLR4 signaling require PI3Ka and TBK1
but not Akt for mTORC1 activation (Fig 6D).
The TBK1-mTORC1 axis induces IFN-b production by promoting
IRF3 nuclear translocation through mTOR S2159 phosphorylation
TLR3- and TLR4-mediated activation of TBK1 and IKKe induce the
production of type I interferons to initiate innate immune responses
against invading microbes (Fitzgerald et al, 2003; Hacker & Karin,
2006; Yu et al, 2012; Schneider et al, 2014). We therefore investi-
gated a role for mTORC1 in production of IFN-b upon poly(I:C) and
LPS treatment of RAW264.7 macrophages and primary BMDMs. As
expected, inhibition of TBK1/IKKe with amlexanox suppressed
IFN-b production in response to poly(I:C) (Fig 7A) and LPS
(Fig EV5A) (6 h), as measured by ELISA. The mTORC1-specific
inhibitor rapamycin also suppressed IFN-b production in response
to both agonists, as did the mTOR inhibitor Ku-0063794 (Figs 7A
and EV5A). Importantly, these pharmacologic agents maintained
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inhibition of mTORC1 signaling at 6 h of agonist stimulation, the
time point used to induce IFN-b (Fig EV5B). To determine whether
mTORC1 inhibition suppresses IFN-b production transcriptionally or
post-transcriptionally, we employed qRT–PCR to measure IFN-b
gene expression. As expected, amlexanox reduced IFN-b mRNA
levels strongly in response to poly(I:C) (Fig 7B) and LPS (Fig EV5C)
A B
C
E
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Figure 4. TBK1 promotes EGF-stimulated mTORC1 signaling and catalytic activity in a manner dependent on site-specific mTOR phosphorylation.
A mTOR S2159 phosphorylation is required for EGF-stimulated mTORC1 signaling. HEK293 cells were co-transfected with vector control, wild-type, or rapamycin-
resistant (RR) AU1-mTOR alleles (RR or RR/S2159A) together with HA-S6K1. Cells were serum-starved (20 h), treated /+ rapamycin (30 min) to ablate endogenous
mTORC1 function, and stimulated /+ EGF [25 ng/ml] (30 min). HA-S6K1 was immunoprecipitated, and immunoprecipitates (IP) and whole-cell lysates (WCL) were
immunoblotted (IB) as indicated. The arrow indicates AU1-mTOR.
B TBK1 is required for EGF-stimulated mTOR auto-phosphorylation. TBK1+/+ and TBK1/ MEFs were serum-starved, EGF stimulated, and analyzed as in (A).
C EGF time course analysis of mTOR auto-phosphorylation. TBK1+/+ and TBK1/ MEFs were serum-starved, EGF stimulated for 0-60 min, and analyzed as in (A).
D TBK1 is required for EGF-stimulated mTOR auto-phosphorylation within mTORC1. TBK1+/+ and TBK1/ MEFs were serum-starved, pre-treated with Ku-0063794
[1 lM], and EGF stimulated as in (A). Raptor was immunoprecipitated, and IPs and WCL were analyzed.
E mTOR S2159 phosphorylation is required for EGF-stimulated mTOR auto-phosphorylation. HEK293 cells were transfected with Myc-mTOR wild type (WT), S2159A, and
kinase dead (KD). Cells were then serum-starved, pre-treated with Ku-0063794 (30 min), and stimulated /+ EGF as in (A).
F Model. EGF-receptor signaling increases mTORC1 signaling through at least three pathways in MEFs: the PI3K/Akt, MAPK, and TBK1 pathways.
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Figure 5. TLR3 and TLR4 promotemTORC1 signaling in a TBK1-dependentmanner in RAW264.7macrophages and primary bonemarrow-derivedmacrophages
(BMDMs).
A Pharmacologic TBK1 inhibition reduces mTORC1 signaling upon activation of TLR3 and TLR4 in cultured macrophages. RAW264.7 cells cultured in full serum were
pre-treated with amlexanox [50 lM or 100 lM] (2 h), rapamycin [20 ng/ml] (30 min), or Ku-0063794 [1 lM] (30 min) and stimulated /+ poly(I:C) [30 lg/ml] or LPS
[100 ng/ml] (60 min). Whole-cell lysate (WCL) was immunoblotted as indicated.
B Knockdown of TBK1 with shRNA reduces TLR3- and TLR4-stimulated mTORC1 signaling. RAW264.7 macrophages were co-infected with shRNA-containing lentiviruses
targeting TBK1 and IKKe shRNA or infected with scrambled control (Scr), selected in puromycin, and treated as in (A).
C Pharmacologic TBK1 inhibition reduces mTORC1 signaling upon activation of TLR3 and TLR4 in primary macrophages. BMDMs were pre-treated with amlexanox
[100 lM] (2 h) or Ku-0063794 [1 lM] (30 min) and stimulated /+ poly(I:C) or LPS as in (A). The arrow indicates S6K1 phosphorylated on T389.
D Pharmacologic TBK1 inhibition reduces mTORC1 signaling upon activation of TLR3 in HEK293-TLR3 cells. Cells were serum-starved (20 h), pre-treated with amlexanox
or Ku-0063794 as in (C) above, and stimulated /+ poly(I:C) [50 lg/ml] (60 min).
E TLR4/LPS-stimulated mTORC1 signaling requires TBK1. TBK1+/+ and TBK1/ MEFs were serum-starved (20 h), pre-treated with amlexanox [50 lM] (2 h) or Torin1
[100 nM] (30 min), and stimulated /+ LPS as in (A).
ª 2017 The Authors The EMBO Journal Vol 37 | No 1 | 2018
Cagri Bodur et al The innate immune kinase TBK1 activates mTORC1 The EMBO Journal
27
(3 h). Rapamycin and Ku-0063794 also reduced levels of IFN-b
mRNA (Figs 7B and EV5C), although not to the same extent as
amlexanox, suggesting that mTORC1 inhibition suppresses IFN-b
production by both transcriptional and post-transcriptional mecha-
nisms. Importantly, rapamycin suppressed IFN-b protein production
in primary BMDMs in response to poly(I:C) (Fig 7C) and LPS
(Fig EV5D) (6 h), indicating that mTORC1 promotes IFN-b produc-
tion in both cultured and primary macrophages.
We next sought to understand the mechanism by which mTORC1
promotes IFN-b production. Upon TLR3 and TLR4 activation by
innate immune agonists, TBK1 phosphorylates IRF3, the transcrip-
tion factor responsible for induction of type I interferons, and
promotes IRF3 dimerization, translocation from the cytosol to
nucleus, and transcriptional activity (Hiscott, 2007; McWhirter et al,
2004; Mori et al, 2004; TenOever et al, 2004; Ikushima et al, 2013).
By employing confocal immunofluorescence microscopy to investi-
gate the subcellular localization of IRF3, we found that rapamycin
blunted the nuclear translocation of IRF3 in response to poly(I:C) in
RAW264.7 macrophages (Fig 7D) and BMDMs (Fig 7E). Rapamycin
also blunted LPS-induced IRF3 translocation in primary BMDMs
A B
C D
Figure 6. TBK1 and mTOR S2159 phosphorylation are required for TLR3- and TLR4-stimulated mTORC1 catalytic activity and signaling.
A, B mTOR S2159 phosphorylation is required for TLR3- and TLR4-stimulated mTORC1 signaling. RAW264.7 macrophages were co-transfected with vector control, wild-
type, or rapamycin-resistant (RR) AU1-mTOR alleles (RR or RR/S2159A) together with HA-S6K1. Cells were treated with rapamycin (+) to ablate endogenous
mTORC1 function and stimulated with poly(I:C) (A) or LPS (B) as in (C). HA-S6K1 was immunoprecipitated, and IPs and WCL was immunoblotted as indicated. The
arrows indicate S6K1 phosphorylated on T389.
C TBK1 activity is required for TLR3- and TLR4-stimulated mTORC1 catalytic activity. RAW264.7 macrophages were pre-treated with amlexanox [50 lM] or [100 lM]
(2 h), rapamycin [20 ng/ml] (30 min), or Ku-0063794 [1 lM] (30 min) and treated /+ poly(I:C) [30 lg/ml] or LPS [100 ng/ml] (60 min). Raptor was
immunoprecipitated (IP), and IPs and whole-cell lysates (WCL) were immunoblotted (IB) as indicated.
D Pharmacologic inhibition of PI3Ka but not Akt reduces TLR3- and TLR4-stimulated mTORC1 signaling. RAW264.7 macrophages were pre-treated with the PI3Ka
class I inhibitor BYL-719 [10 lM], the Akt inhibitor MK-2206 [10 lM], amlexanox [100 lM], or Ku-0063794 [1 lM] (30 min) and stimulated /+ poly(I:C) or LPS as
in (C).
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Figure 7. mTORC1 function and mTOR S2159 phosphorylation are required for TLR3-stimulated IFN-b production in cultured and primary macrophages by
promoting IRF3 nuclear translocation.
A Rapamycin suppresses TLR3-stimulated IFN-b protein production in cultured macrophages. RAW264.7 macrophages were pre-treated with rapamycin [20 ng/ml]
(30 min), Ku-0063794 [1 lM] (30 min), or amlexanox [50 lM] (2 h) and stimulated /+ poly(I:C) [30 lg/ml] for 6 h. The secretion of IFN-b was measured by ELISA.
Results represent the mean  SD of quadruplicate samples from one experiment. *P = 0.0009 relative to +poly(I:C) by paired t-test (two-tailed).
B Rapamycin suppresses TLR3-stimulated IFN-b mRNA production in cultured macrophages. RAW264.7 macrophages were treated as above but stimulated
/+ poly(I:C) [30 lg/ml] for 3 h. IFN-b gene expression was measured by qRT–PCR. Results represent the mean  SD of triplicate samples from one experiment.
*P = 0.03 relative to no poly(I:C) by paired t-test (one-tailed); **P = 0.04 relative to +poly(I:C) by paired t-test (one-tailed).
C Rapamycin suppresses TLR3-stimulated IFN-b protein production in primary macrophages. BMDMs were pre-treated with rapamycin or amlexanox and analyzed as
in (A). Results represent the mean  SD of triplicate samples from one experiment. *P = 0.002 relative to +poly(I:C) by paired t-test (two-tailed).
D Rapamycin suppresses TLR3-stimulated IRF3 nuclear translocation in RAW264.7 macrophages. Cells were pre-treated with rapamycin and stimulated /+ poly(I:C) for
3 h as in (A), fixed, and processed for confocal immunofluorescence microscopy using an anti-IRF3-Alexa 488 antibody and DAPI staining. The graph represents the
mean  SD of at least 400 cells total from three independent experiments. *P = 0.002 relative to no poly(I:C) by paired t-test (two-tailed); **P = 0.003 relative to
+poly(I:C) by paired t-test (two-tailed). Scale bar = 10 lm.
E Rapamycin suppresses TLR3-stimulated IRF3 nuclear translocation in primary BMDMs. Cells were pre-treated with rapamycin and stimulated /+ poly(I:C) for 3 h as
in (A), fixed, and processed for confocal immunofluorescence microscopy using an anti-IRF3-Alexa 488 antibody and DAPI stain. The graph represents the mean  SD
of at least 380 cells total from three independent experiments. *P = 0.003 relative to no poly(I:C) by paired t-test (two-tailed); **P = 0.005 relative to +poly(I:C) by
paired t-test (two-tailed). Scale bar = 10 lm. Note: the untreated control image is the same as the untreated control image in Fig EV5E.
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(Fig EV5E). Our finding that mTORC1 promotes IRF3 nuclear
translocation provides a mechanistic basis for how rapamycin
reduces IFN-b gene expression.
To investigate a direct mechanistic link between TBK1 and
mTOR with regards to mTORC1 signaling and cellular innate
immune function, we studied primary BMDMs isolated from
genome edited mice bearing an alanine knock-in substitution at
S2159 in the mTOR gene using CRISPR/Cas9 technology (Fig EV6A
and B). In response to TLR3 (Fig 8A) and TLR4 (Fig 8B) activation
with poly(I:C) and LPS, respectively, mTORC1 signaling was
impaired in homozygous mutant mTORA/A primary BMDMs
compared to wild-type mTOR+/+ macrophages. We next investi-
gated a role for mTOR S2159 phosphorylation in IFN-b production
and IRF3 nuclear translocation. In primary BMDMs cultured in full
serum-containing media, we noted differences in IFN-b production
by mTOR+/+ vs. mTORA/A macrophages in some experiments but
not others. To reduce this variability, we serum-starved the macro-
phages gently (6 h) prior to stimulation with poly(I:C) to reduce the
potential effects of growth factor action on mTORC1. mTORA/A
macrophages produced less IFN-b in response to poly(I:C) than
mTOR+/+ macrophages (Fig 8C). Moreover, IRF3 nuclear transloca-
tion was reduced in mTORA/A macrophages relative to mTOR+/+
macrophages (Fig 8D). Collectively, these data support a model
whereby TBK1-mediated mTOR phosphorylation on S2159 increases
mTORC1 catalytic activity and signaling upon activation of TLR3 or
TLR4. mTORC1 then induces the translocation of IRF3 from the
cytoplasm to the nucleus and thus cooperates with TBK1 to promote
IFN-b production (Fig 8E).
Discussion
In addition to classical roles in innate immunity and inflamma-
tion to combat infectious pathogens, TBK1 and IKKe have been
linked to tumorigenesis during oncogenic stress and metabolic
control during obesity (Chiang et al, 2009; Shen & Hahn, 2011;
Helgason et al, 2013; Reilly et al, 2013). The role of TBK1/IKKe
in diverse cellular processes suggests that these kinases likely
possess multiple substrates that control cell physiology in cell
context-dependent manners. Here we demonstrate that TBK1
phosphorylates mTOR directly to increase mTORC1 catalytic
activity and signaling, thus identifying mTORC1 as a new TBK1
substrate and TBK1 as a new mTORC1 activator. While challeng-
ing to prove definitively that a kinase phosphorylates a substrate
directly in intact cells, our collective data support the notion that
mTORC1 represents a bona fide TBK1 substrate. For example,
recombinant TBK1 as well as Flag-TBK1 immunoprecipitated from
intact cells phosphorylates mTOR in vitro, Flag-TBK1 expressed
ectopically in cells increases mTOR phosphorylation, treatment of
cells with EGF increases mTOR phosphorylation in TBK1+/+ but
not TBK1/ MEFs, and TBK1 interacts with mTORC1 in intact
cells. Multiple approaches including genetic knockout and knock-
in, pharmacological inhibition, and RNAi demonstrate that
mTORC1 signaling requires TBK1 downstream of EGF-receptor
and TLR3/4. By studying cultured cells expressing an ectopic
mTOR S2159 Ala substitution mutant or primary macrophages
derived from genetically modified mice bearing germline mTOR
S2159A knock-in mutation (mTORA/A), we show that
phosphorylation of mTOR on a TBK1 site (S2159) promotes
mTORC1 signaling in response to EGF and innate immune
agonists. These data demonstrate a direct mechanistic link
between TBK1 and mTORC1 and cross talk between these impor-
tant signaling systems. To gain greater insight into the physio-
logic relevance of the TBK1-mTORC1 axis in control of innate
immune function, we measured IFN-b production, a major cellu-
lar function controlled by TBK1. Pharmacological inhibition of
mTORC1 with rapamycin in cultured macrophages (RAW264.7)
and primary macrophages (BMDMs) suppressed IFN-b production
upon TLR3 or TLR4 activation through a mechanism involving
reduced translocation of the transcription factor IRF3 from the
cytosol into the nucleus. Analysis of primary macrophages
derived from our mTORA/A knock-in mice revealed that TBK1
promotes IRF3 translocation and IFN-b production through site-
specific mTOR phosphorylation.
Consistent with our work, other studies reported that TBK1 inter-
acts with mTOR (Kim et al, 2013; Hasan et al, 2017). Paradoxically,
however, these studies concluded that TBK1 inhibits mTORC1.
While we do not fully understand this discrepancy, the cellular
contexts of these studies were quite different from ours. Kim et al
(2013) studied prostate cancer cells and found that overexpression
of TBK1 reduced S6K1 T389 phosphorylation. Similarly, we find that
TBK1 overexpression inhibits mTORC1 signaling (see Fig EV2B).
We have thus avoided TBK1 overexpression as an approach when
studying mTORC1 signaling. It is important to note that raptor, a
scaffolding protein and mTOR partner essential for mTORC1 signal-
ing, also suppresses S6K1 phosphorylation when overexpressed.
Hasan et al (2017) studied MEFs from mice lacking Trex, a clinical
model of autoimmune/autoinflammatory disease. Knockout of the
Trex exonuclease in MEFs activates the cytosolic DNA sensing
cGAS-STING-TBK1 pathway; these MEFs also exhibit reduced
mTORC1 signaling relative to Trex+/+ MEFs (Hasan et al, 2017).
As both TBK1 and mTORC1 engage in negative feedback, it is possi-
ble that chronic loss of Trex re-wires cell signaling that impacts the
mTORC1 pathway negatively.
Our work demonstrates a dominant role for TBK1 in EGF- but
not insulin-stimulated mTORC1 signaling, revealing a stimulus-
selective role for TBK1 in mTORC1 regulation by growth factors.
Interestingly, data shown but not discussed in an earlier report
agrees with this finding (Ou et al, 2011). Consistently, cells reliant
on an mTOR S2159A allele show impaired mTORC1 signaling in
response to EGF but not insulin [see Fig 4A and Ekim et al (2011)].
How TBK1 contributes selectively to mTORC1 activation by growth
factors remains an important question. EGF but not insulin may
activate TBK1. Indeed, an earlier report found that cellular EGF
stimulation increases the kinase activity of immunoprecipitated
TBK1 toward substrate in vitro (Ou et al, 2011), suggesting that
EGF-receptor signaling increases TBK1 intrinsic catalytic activity.
Consistently, we found that EGF but not insulin increases mTOR
S2159 phosphorylation in intact cells (see Fig 2H). As TBK1 inter-
acts with mutually exclusive scaffolding partners, TBK1 activation
may be governed by recruitment of TBK1 to specific signaling plat-
forms (Ma et al, 2012; Helgason et al, 2013). These platforms may
contain a TBK1 activating kinase or promote local clustering of
TBK1, enabling kinase domain interaction and activation loop swap-
ping, leading to trans auto-phosphorylation and auto-activation (Ma
et al, 2012; Helgason et al, 2013). Alternately, the EGF but not
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insulin pathway may drive co-localization of TBK1 with substrate
(i.e., mTOR) (Helgason et al, 2013). It is important to note that
while LPS or poly(I:C) increased TBK1 S172 phosphorylation and
mTORC1 signaling in MEFs and HEK293/TLR3 cells, respectively,
EGF failed to increase P-TBK1-S172 (see Fig EV2A and B) while it
increased mTORC1 signaling. What do these unexpected
A
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Figure 8. mTOR S2159 phosphorylation promotes mTORC1 signaling, IRF3 nuclear translocation, and IFN-b production upon TLR3 activation in primary
macrophages.
A Reduced TLR3-inducedmTORC1 signaling inmTOR S2159A knock-in primarymacrophages (mTORA/A) relative to wild type (mTOR+/+): BMDMswere pre-treated with Torin 1
[100 nM] (30 min) and stimulated/+ poly(I:C) [30 lg/ml] for 30 min.Whole-cell lysate (WCL) was immunoblotted as indicated. The graph quantitates three independent
experiments eachwith n = 1 (n = 3 total). The level of P-S6K1-T389 normalized to total protein inmTOR+/+ macrophages stimulated with poly(I:C) was set at 100%. The
other bars representmean  SD as a relative percent. *The confidence interval at 95% (52.7–59.1) indicates statistical significance betweenmTOR+/+ vs. mTORA/A BMDMs.
B Reduced TLR4-induced mTORC1 signaling in mTORA/A primary macrophages. BMDMs were treated as in (A) except stimulated /+ LPS [100 ng/ml] (30 min). The
graph quantitates three independent experiments each with n = 1 (n = 3 total). The level of P-S6K1-T389 normalized to total protein in mTOR+/+ macrophages
stimulated with LPS was set at 100%. The other bars represent mean  SD as a relative percent. *The confidence interval at 95% (58.6–71.2%) indicates statistical
significance between mTOR+/+ vs. mTORA/A BMDMs.
C Reduced TLR3-stimulated IFN-b protein production in mTORA/A primary macrophages. BMDMs were serum-starved for 6 h and stimulated /+ poly(I:C) [30 lg/ml] for
6 h. The secretion of IFN-b was measured by ELISA. Results represent the mean  SEM from three independent experiments, n = 8 samples total. *P = 0.0002
relative to mTOR+/+ + poly(I:C) by unpaired t-test (equal variance; two-tailed). **P = 0.0001 relative to mTOR+/+ + poly(I:C) by paired t-test (two-tailed).
D Reduced TLR3-stimulated IRF3 nuclear translocation in mTORA/A primary macrophages. BMDMs were treated /+ poly(I:C) for 3 h as in (A), fixed, and processed for
confocal immunofluorescence microscopy using an anti-IRF3-Alexa 488 antibody and DAPI stain. The graph represents the mean  SEM of at least 270 cells total
from four independent experiments. *P = 0.001 relative to mTOR+/+ no poly(I:C) by unpaired t-test (equal variance; two-tailed). **P = 0.02 relative to mTOR+/+ +
poly(I:C) by unpaired t-test (equal variance; two-tailed). Scale bar = 10 lm.
E Model. TLR3 and TLR4 signaling increases TBK1-mediated mTOR S2159 phosphorylation, resulting in increased mTORC1 catalytic activity, mTORC1 downstream
signaling, IRF3 nuclear translocation, and IFN-b production.
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observations mean? While we do not know at the moment, these
data may suggest that EGF-receptor signaling does not increase
TBK1 intrinsic catalytic activity, which can be monitored by phos-
phorylation on the TBK1 activation loop site (S172). In this case,
basal TBK1 kinase activity would “prime” mTOR for EGF-stimulated
activation of mTORC1. Alternately, the data may suggest that the
mechanism by which innate immune agonists vs. EGF activate
TBK1 differs; in this scenario, immunoblotting with P-TBK1-S172
antibodies does not represent a reliable readout for TBK1 activation
in response to EGF.
Downstream of EGF-receptor, KRAS signaling activates TBK1
through Ral-GEF, the guanine nucleotide exchange factor for the
RalA and RalB GTPases (Zhu et al, 2014; Kitajima et al, 2016).
Active GTP-loaded RalB and its effector Sec5 recruit and activate
TBK1 by an unclear mechanism (Chien et al, 2006). Interestingly,
RalB and Sec5 were reported to promote mTORC1 signaling through
an unknown mechanism (Martin et al, 2014). Our work suggests
that TBK1 may represent the missing link between RalB/Sec5 and
mTORC1. Our data also demonstrate that EGF and insulin increase
Akt S473 phosphorylation in a TBK1- and mTOR-dependent manner
(see Fig 2F). While not defined mechanistically at this time, these
data indicate that TBK1 contributes to mTORC2 activation in
response to both EGF and insulin. It is important to note that our
observed dependency of Akt S473 phosphorylation on TBK1 agrees
with published work (Joung et al, 2011; Ou et al, 2011; Xie et al,
2011). Two of these studies concluded, however, that TBK1 phos-
phorylates Akt S473 directly independently of mTORC2 (Ou et al,
2011; Xie et al, 2011). In the cells studied here, however (i.e., MEFs;
HEK293; RAW264.7), Akt S473 phosphorylation stimulated by
growth factors or innate immune agonists depended strongly on
mTOR. Perhaps TBK1 phosphorylates Akt directly in certain physio-
logic or pathological contexts.
Our results provide greater mechanistic insight into how
mTORC1 modulates innate immune function, identifying mTORC1
as a direct effector of TBK1 that promotes IRF3 nuclear translocation
and IFN-b production. While it is well established that TBK1 induces
IFN-b production downstream of TLR3 and TLR4 by promoting the
dimerization, nuclear translocation, and transcriptional activation of
IRF3 in cooperation with the co-activator CBP/p300 (McWhirter
et al, 2004; Mori et al, 2004; TenOever et al, 2004; Hiscott, 2007),
many unresolved issues remain regarding the kinases that phospho-
rylate IRF3 on its many sites and the functional consequences of
these phosphorylation events. It has been suggested that TBK1-
mediated phosphorylation of a cluster of C-terminal sites (S396;
S398; S402; T404; S405) alleviates structural auto-inhibition and
increases transcriptional activity, enabling IRF3 phosphorylation on
nearby sites (S385; S386), which induces dimerization and nuclear
translocation (McWhirter et al, 2004; Mori et al, 2004; Panne et al,
2007). As mTORC1 function is required for IRF3 nuclear transloca-
tion, it is tempting to speculate that mTORC1 itself or a downstream
kinase (i.e., S6K1) may phosphorylate IRF3 to promote dimerization
and/or nuclear translocation, thus cooperating with TBK1 to drive
IFN-b production.
It is important to note that a limited number of reports in the
literature have noted connections between the mTORC1 pathway
and TLR-mediated innate immune responses. Rapamycin
suppressed IFN-b production upon TLR3 activation in human oral
keratinocytes (Zhao et al, 2010), and rapamycin administered
in vivo delayed the mortality of mice injected with a lethal dose of
LPS (aka endotoxin) by blunting production of several cytokines
including IFN-c (Lee et al, 2010). In response to vesicular stomati-
tis virus (VSV), which activates TBK1 (TenOever et al, 2007), mice
and MEFs lacking S6K1 and 2 were more susceptible to infection
than wild-type controls due to impaired production of type I inter-
ferons (Alain et al, 2010). In addition, MEFs lacking other
mTORC1 substrates- 4EBP1 and 4EBP2, repressors of eIF4E
controlled cap-dependent translation- produced higher levels of
type I IFNs in response to TLR3 activation (Colina et al, 2008;
Erickson & Gale, 2008). Moreover, these 4EBP1/2 knockout mice
exhibited resistance to VSV infection (Colina et al, 2008; Erickson
& Gale, 2008). Increased translational efficiency of IRF7, which
drives IFN-b expression to high levels after an initial wave of
IRF3-mediated transcriptional induction of IRF7 (through a positive
feedback loop), was found to underlie these effects in 4EBP1/2
null MEFs (Colina et al, 2008). Thus, mTORC1 promotes IFN-b
production through parallel effector pathways involving S6Ks and
4EBPs. As cap-dependent translation represents a major cellular
function controlled by mTORC1 (Ma & Blenis, 2009), it will be
interesting to investigate whether mTORC1 plays a more global
role in innate immunity via translational control. More recently,
the cytosolic DNA sensing cGAS-STING-TBK1 pathway was shown
to activate IRF3 in a manner that required the mTORC1 substrate
S6K1 (but not its kinase activity; Wang et al, 2016). Other work
reveals roles for mTORC1 in control of interferon production
downstream of TLR7 and TLR9 (Cao et al, 2008; Schmitz et al,
2008; Boor et al, 2013). Beyond its role in innate immunity, TBK1
promotes tumorigenic processes and modulates metabolism. TBK1
is required for anchorage-independent proliferation and survival of
non-small cell lung cancer (NSCLC) cells and cultured cells trans-
formed with oncogenic KRAS (Chien et al, 2006; Barbie et al,
2009; Ou et al, 2011; Xie et al, 2011). With regard to metabolic
control, tissue from obese mice experiencing chronic low-grade
inflammation (i.e., liver; adipocytes; adipose tissue macrophages)
exhibits elevated expression of TBK1 and IKKe downstream of
NF-jB; in addition, TBK1/IKKe have been linked to increased
glucose uptake in adipocytes, increased whole-body energy storage
during obesity, and suppression of catecholamine-induced lipolysis
(Chiang et al, 2009; Mowers et al, 2013; Reilly et al, 2013; Uhm
et al, 2017). Curiously, certain phenotypes resulting from tissue-
specific knockout of raptor (mTORC1) or rictor (mTORC2) from
metabolic tissues (i.e., adipose; liver; skeletal muscle) in mice
align with these metabolic functions of TBK1 (Kumar et al, 2008,
2010; Polak et al, 2008; Hagiwara et al, 2012; Lee et al, 2016;
Kleinert et al, 2017).
Our identification of TBK1 as a direct upstream activator of
mTORC1- and possibly mTORC2- suggests new roles for mTORCs as
downstream TBK1 effectors that control innate immunity and
contribute to disorders such as tumorigenesis, metabolic diseases,
and autoimmune diseases (Shen & Hahn, 2011; Yu et al, 2012;
Reilly et al, 2013). Our mTORA/A mouse model represents an impor-
tant tool for future investigation into roles for the TBK1-mTOR axis
in vivo in control of normal physiology and pathophysiology. Addi-
tional important questions remain. The upstream signaling interme-
diates controlling the activation state of the TBK1-mTORC1 axis
during growth factor and innate immune signaling remain incom-
pletely defined as does the relative contribution of IKKe to mTORC
The EMBO Journal Vol 37 | No 1 | 2018 ª 2017 The Authors
The EMBO Journal The innate immune kinase TBK1 activates mTORC1 Cagri Bodur et al
32
regulation. Moreover, the molecular mechanisms by which TBK1
promotes mTORC2 signaling and by which mTORC1 promotes IRF3
nuclear translocation remain unresolved. Collectively our work
reveals new crosstalk between two important signaling systems that
coordinate cellular responses to growth factors and innate immune
agonists.
Materials and Methods
Materials
All chemicals were from either Fisher Chemicals or Sigma. Protein
A- and G-Sepharose Fast Flow and glutathione-Sepharose beads
were from GE Healthcare; 3-[(3-cholamidopropyl)-dimethy-
lammonio]-1-propanesulfonate (CHAPS) was from Pierce; Immo-
bilon-P polyvinylidene difluoride (PVDF) membrane (0.45 lM) was
from Millipore, and reagents for enhanced chemiluminescence
(ECL) were from Millipore (Immobilon Western chemiluminescent
horseradish peroxidase [HRP] substrate) or Advansta (Wester-
nBright Sirius HRP substrate). Recombinant TBK1 (#PV3504) and
recombinant IKKe (#PV4875) proteins were from Invitrogen/Life
Technologies.
Antibodies
Myc-9E10 (#MMS-150P) and HA.11 (#MMS-101P) monoclonal anti-
bodies for immunoprecipitation and immunoblotting were from
Covance, now Biolegend. Flag-M2 monoclonal antibody was from
Sigma (#F3165). AU1 monoclonal antibody was from Biolegend
(#903101). The following commercial antibodies were from Cell
Signaling Technology: mTOR (#2972); P-S6K1-T389 (rabbit mono-
clonal 108D2; #9234); P-4EBP1-T37/46 (#9459); P-4EBP1-T70
(#9455); P-4EBP1-S65 (#9451); non-P-4EBP1-T46 (#4923); 4EBP1
(#9452); GST (#2625); P-Akt-S473 (#4060); Akt (#9272); P-TBK1-
S172 (#5483); TBK1 (#3504); P-IKKe-S172 (#8766); IKKe (#3416);
P-IRF3-S396 (#4947); IRF3 (#4302). P-mTOR-S2481 was from Milli-
pore (#09-343). Commercial polyclonal antibodies to raptor were
from Millipore (#09-217). Several polyclonal antibodies to the
following proteins were generated in-house using a Covance custom
antibody service, as described in (Acosta-Jaquez et al, 2009): Raptor
(amino acids 1–17 or 885–901; human); mTOR (amino acids 221–
237; rat); rictor (amino acids 6–20; human); S6K1 (amino acids 485–
502 of the 70 kDa isoform; rat). mTOR P-S2159 antibodies (amino
acids 2154–2163; rat) were generated in collaboration with Millipore
(#ABS79), as described (Ekim et al, 2011) (note that the mTOR P-
S2159 possesses weak phospho reactivity). Donkey anti-rabbit-HRP
secondary antibody was from Jackson (#711-095-152), and sheep
anti-mouse-HRP was from GE Healthcare (#NA931V).
Plasmids
pRK5/Myc-mTOR and pRK5/HA-raptor plasmids were obtained from
D. Sabatini via Addgene (#1861 and 8513, respectively); pcDNA3/
AU1-mTOR (wild-type and rapamycin-resistant (S2035I) alleles)
were from R. Abraham (Burnham Institute of Medical Research,
La Jolla, CA); pRK7/HA-S6K1 was from J. Blenis (Weill
Cornell Medical College, New York, NY); pcDNA3/Flag-TBK1,
pcDNA3/Flag-TBK1-kinase-dead (K38A), pcDNA3/Flag-IKKe, and
pcDNA3/Flag-IKKe-kinase-dead (K38A) plasmids were from A.
Saltiel (University of Michigan, Ann Arbor, MI). mTOR S2159A and
S2159D mutants in the rapamycin-resistant (S2035I) backbone of
AU1-mTOR were generated as described previously using site-
directed mutagenesis (QuikChange II XL; Stratagene; Ekim et al,
2011).
Cell culture, transfection, and drug treatments
HEK293-TLR3 cells were obtained from K. Fitzgerald (University
of Massachusetts Medical School, Worcester, MA). TBK1+/+ and
TBK1/ MEFs were from K.L. Guan (University of California San
Diego, La Jolla, CA). RAW264.7 murine macrophages were from
A. Saltiel (University of Michigan, Life Sciences Institute, Ann
Arbor, MI). All cell lines were cultured in DMEM that contained
high glucose [4.5 g/l], glutamine [584 mg/l], and sodium pyru-
vate [110 mg/l] (Life Technologies/Invitrogen) supplemented with
10% fetal bovine serum (FBS) (Gibco/Invitrogen; except that
heat-inactivated FBS was used for RAW264.7 murine macro-
phages) and incubated at 37°C in a humidified atmosphere
containing 5% CO2. HEK293 cells were transfected according to
manufacturer’s directions using TransIT-LT1 (Mirus). TBK1/
MEFs and RAW264.7 macrophages were transfected using
JetPRIME transfection reagent (Polyplus Transfection). Cells were
lysed ~24–48 h post-transfection. TBK1+/+ and TBK1/ MEFs
that had been serum-starved for ~20 h (in DMEM containing
20 mM Hepes pH7.2) were stimulated with insulin [100 nM]
(Invitrogen; #12585) or epidermal growth factor (EGF) [100 lg/
ml] (Sigma; #E4127) for 30 min. Serum-starved HEK293-TLR3
cells were stimulated with poly(I:C) (Sigma; #P1530) [50 lg/ml]
for 2 h RAW264.7 macrophages cultured under steady-state condi-
tions (DMEM/FBS) were stimulated with poly I:C [30 lg/ml] or
ultrapure LPS [100 ng/ml] (InVivo Gen #tlrl-3pelps) for times
indicated in the figure legend. The Invitrogen Flp-In system was
used to generate HEK293T cell lines that express stably
AU1-mTOR, as described (Ekim et al, 2011). The following drugs
were employed: Amlexanox [100 lM] (Tocris #485710), BX-795
[10 lM] (Millipore/CalBiochem #204011), MRT-67307 [10 lM]
(Millipore/CalBiochem #506306), rapamycin [20 ng/ml] (Cal-
biochem #553210); Ku-0063794 [100 nM] (Tocris #3725); BYL-719
[10 lM] (Selleck #S1020); MK-2206 [10 lM] (Selleck #S1078);
CI-1040 [10 lM] (Selleck #S2814).
Cell lysis, immunoprecipitation, and immunoblotting
Unless indicated otherwise, cells were washed twice with ice-cold
PBS and lysed in ice-cold buffer A containing NP-40 [0.5%] and
Brij35 [0.1%], as described (Acosta-Jaquez et al, 2009). To maintain
the detergent sensitive mTOR-raptor interaction, cells were lysed in
ice-cold buffer A containing CHAPS [0.3%]. Lysates were spun at
16,100 rcf for 5 min at 4°C, and the post-nuclear supernatants were
collected. Bradford assay was used to normalize protein levels for
immunoprecipitation and immunoblot analysis. For immunoprecipi-
tation, whole-cell lysates were incubated with antibodies for 2 h at
4°C, followed by incubation with Protein G- or A-Sepharose beads
for 1 h. Sepharose beads were washed three times in lysis buffer
and resuspended in 1× sample buffer. Samples were resolved on
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SDS–PAGE and transferred to PVDF membranes by using Towbin
transfer buffer. Immunoblotting was performed by blocking PVDF
membranes in Tris-buffered saline (TBS) pH 7.5 with 0.1% Tween
20 (TBST) containing 3% non-fat milk and incubating the
membranes in TBST with 2% bovine serum albumin (BSA) contain-
ing primary antibodies or secondary HRP-conjugated antibodies.
Blots were developed by ECL and detected digitally with a Chemi-
Doc-It System (UVP).
In vitro kinase assays
Generation of recombinant GST-mTOR for in vitro kinase assays
A fragment of mTOR encoding amino acids 2,144–2,175 (wild
type and a S2159A/T2164A mutant) was subcloned via PCR into
vector pGEX-20T for production of GST fusion proteins in the
bacterial strain BL21(DE3)LysS. The following primers were used
to PCR amplify the mTOR fragment: Primer 1, 50-gactggatcctatgac
cccaaccagccaatc-30; primer 2, 50-gactgaattcgcccatcagggtcagcttccg-30.
GST-mTOR was affinity purified on glutathione-sepharose beads
via a standard protocol and dialyzed against 10 mM Tris pH 7.4,
100 mM NaCl, 1 mM EDTA, 154 mg/L DTT, and 5% glycerol.
In vitro kinome screen
The in vitro kinome screen was performed in collaboration with
Invitrogen/Life Technologies. ~300 recombinant human kinases
arrayed on a 384-well plate were incubated with GST-mTOR
substrate [0.125 mg/ml] substrate in reactions containing 25 nM
recombinant kinases and ATP [1 mM, 50 mM HEPES pH 7.5,
10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35. Reactions were
incubated at room temperature for 1 h. Dot blots of the kinase reac-
tions were imaged after incubation with P-mTOR-S2159 primary
antibody and Alexa Fluor 488 anti-rabbit secondary antibody. Incor-
poration of [32P]-ATP was performed similarly, except that reactions
contained 20 nM recombinant kinase, 0.11 mg/ml GST-mTOR (WT
or AA), cold ATP [0.1 mM], and trace [c32P]-ATP. After 1 h incuba-
tion at room temperature, reactions were spotted on nitrocellulose,
washed with phosphoric acid and water, and then imaged.
Conventional in vitro kinase (IVK) assays
In vitro kinase assays were performed by incubating recombinant
GST-mTOR ~ [200 ng] or immunoprecipitated Myc-mTOR substrate
with ATP [250 lM] and recombinant [~50 ng/reaction] or immuno-
precipitated TBK1/IKKe in kinase buffer containing 50 mM Tris pH
7.5, 12 mM MgCl2, and 1 mM b-glycerophosphate. Reactions were
incubated at 30°C for 30 min and stopped by addition of sample
buffer followed by incubation at 95°C for 5 min. Samples were
resolved on SDS–PAGE, transferred to PVDF membrane, and
immunoblotted with P-mTOR S2159 antibodies. For drug pre-treat-
ments, recombinant kinases were pre-incubated with amlexanox
[100 lM], BX-795 [10 lM], MRT-67307 [10 lM], or in kinase buffer
on ice for 30 min.
In vivo LPS treatment
Mice (C57BL6) were housed in a specific pathogen-free facility with
a 12-h light/12-h dark cycle and given free access to food and water.
All animal use was in compliance with the Institute of Laboratory
Animal Research Guide for the Care and Use of Laboratory Animals
and approved by the University Committee on Use and Care of
Animals at the University of Michigan. To determine the response
upon LPS, mice at 6-week-old were administered by an intraperi-
toneal injection of PBS, LPS [1 mg/kg BW] for 2 h. Spleens were
dissected and homogenized for western blot analysis.
Generation of rictor/ MEFs stably expressing HA-Rictor by
lentiviral transduction
A HA-tagged rictor cDNA was subcloned into a modified lentiviral
vector, pHAGE-Puro-MCS (pPPM) (modified by Amy Hudson; Medi-
cal College of WI). Lentivirus particles were packaged in HEK293T
cells by co-transfecting empty pPPM vector or pPPM/HA-Rictor
together with pRC/Tat, pRC/Rev, pRC/gag-pol and pMD/VSV-G
using Mirus TransIT-LT1 transfection reagent. Supernatants contain-
ing viral particles were collected 48 h post-transfection and filtered
through a 0.45-lm filter. Rictor/ MEFs were infected with fresh
supernatants with 8 lg/ml polybrene. 24 h post-infection, cells were
selected in DMEM/10% FBS supplemented with 3 lg/ml puromycin.
shRNA interference
RAW264.7 macrophages were co-infected with lentiviral shRNAs
targeting TBK1 and IKKe (Sigma; mouse TBK1 # TRCN0000323444;
mouse IKBKE (IKKe) # TRCN 0000026722; non-targeting
# SHC016V) and then selected in puromycin [8 lg/ml] for 4 days.
siRNA interference
RAW264.7 macrophages were transfected with On-TARGETplus
siRNA SMARTpool reagents [100 nM] (Dharmacon-GE Healthcare)
targeting TBK1 and IKKe using Lipofectamine RNAiMAX (Invitro-
gen) according to the manufacturer’s instructions (mouse TBK1 #L-
063162; mouse IKBKE (IKKe) #L-040798; non-targeting #D-001810).
Cells were re-fed 2 h prior to lysis 5 days post-transfection.
IFN-b ELISA
RAW264.7 macrophages or primary BMDMs (from 8- to 16-week-
old mice) were treated with poly(I:C) [30 lg/ml] or LPS [100 ng/
ml] (6 h). Medium was collected to quantify IFN-b secretion using
the mouse IFN-b ELISA Kit (R&D Systems; 42400-1) according to
manufacturer’s directions. Protein assays were used to normalized
cell number per well to compare IFN-b production in wild-type vs.
S2159 primary BMDMs.
qRT–PCR
Total RNA was extracted from RAW264.7 cells using an RNeasy Plus
Mini Kit (Qiagen) according to manufacturer’s instruction, and 250 ng
total RNA was reverse transcribed into cDNA using High Capacity
RNA to cDNA Kit (Applied Biosystems). Quantitative polymerase
chain reaction (qPCR) was performed using TaqMan Fast Advanced
Master Mix on a StepOne Plus Real-Time PCR System (Applied Bio-
systems). cDNA was diluted ten times prior to qRT–PCR. Relative
quantification was performed by 2DDCt methodology (Livak and
Schmittgen, 2001). TaqMan primer/probe sets for mouse IFN-b1
(Mm00439552-s1) and GAPDH (Mm99999915-g1) genes were
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purchased from Applied Biosystems. Amplification specificity was con-
firmed with agarose gel electrophoresis of the reaction products. cDNA
was diluted ten times for qRT–PCR using TaqMan Fast Advanced
Master Mix. StepOne Plus Real-Time PCR System (Applied Biosys-
tems). GAPDH was used as an endogenous control for normalization.
Isolation of primary bone marrow-derived
macrophages–monocytes
Bone marrow was harvested by flushing femora, tibiae and humeri
from 8-week-old WT mice with 1 ml of ice-cold PBS with a 30G
needle (BD) under sterile conditions. Bone marrow cells were
suspended in MEM with L-glutamine supplemented with 10%
HI-FBS, 50 U/ml penicillin, 50 lg/ml streptomycin, and 20 ng/ml
M-CSF (R&D Systems) and were plated into 6-well tissue culture
plates with a density of 3 × 106/well. Cells were incubated at
7.5% CO2, at 37°C, and medium was replaced every 2 days
until the 7th day when the experiments were done at around 50%
confluency.
IRF3 translocation by confocal microscopy
Cells were seeded in 6-well plates containing glass coverslips in
appropriate culture medium. Following various treatments, cells
were washed with PBS and fixed with 3.7% formaldehyde for
10 min. Upon quenching the fixative 5 min with 50 mM NH4Cl,
cells were permeabilized 5 min in 0.2% TX-100 and blocked 1 h in
0.2% fish skin gelatin. Coverslips were inverted on Alexa 488-conju-
gated anti-IRF3 antibody (1:100) (Abcam # ab204647) for 1 h,
followed by mounting in Prolong Gold with DAPI (Invitrogen).
Slides were visualized using a Nikon A1 confocal microscope. To
quantify IRF3 nuclear to cytosolic subcellular distribution, DAPI-
stained nuclear regions of individual cells and the whole field of
view containing all cells were each selected using a drawing tool in
Image J. Background FITC signal was calculated from cell-free
regions and subtracted from calculations. Cytoplasmic IRF3 was
determined by subtracting the total nuclear FITC intensity from the
total FITC intensity of the whole area. Mean nuclear to cytoplasmic
ratio  SD was calculated from ratios of nuclear intensities divided
by cytoplasmic intensities.
Generation of genetically modified mice bearing a germline
mTOR knock-in S2159A allele using CRISPR-Cas9 genome
editing technology
A 20-nucleotide guide sequence targeting genomic mTOR upstream
of S2159 was subcloned into pX330. Forward sequence: 50-caccgtg-
gttggggtcgtatgttcc; reverse sequence: 50-aaacggaacatacgaccccaaccac.
The following single-stranded oligonucleotide served as repair
template, which includes the targeted sequence (underlined), left
and right homology arms, and the serine 2159 to alanine mutation
(also underlined; tct to Gct): 50-gttcaaagctcacatccctggagctgcagtat
gtgtcccccaaacttctgatgtgccgagaccttgagttggctgtg[ccCggG]acataTgacccAa
accagccaatcattcgcattcaatccatagccccgGctttgcaagtcatcacatccaagcagaggc
ctcgg aagctgactctga-30.
The repair template also included several silent mutations
(capitalized) to prevent re-targeting of edited genomic signals,
plus a new SmaI restriction site ([ccCggG]) to facilitate
genotyping. The gRNA targeting plasmid (pX330-mTOR) and the
repair template were co-microinjected into single-cell fertilized
mouse oocytes and implanted into a pseudo-pregnant mouse.
Heterozygous founders were identified through SmaI restriction of
genomic DNA. To confirm co-recombination of both the SmaI site
and the S2159 to Ala mutation, the genomic region was TOPO
cloned and sequenced.
The following PCR primers were used for TOPO cloning: Forward-
50-ATC CAG ACT CGC TTC TGC TGG AGA-30; reverse- 50-CTT TCT
CAT CCA ACA GAC ATG GGG GAGT-30.
To generate mTORA/A homozygous mice, mice heterozygous for
mTOR S2159A were mated (mTOR+/mTORA x mTOR+/mTORA).
These mice were generated with the assistance of the Molecular
Genetics Core of the MDRC (Michigan Diabetes Research Center)
and the UM Transgenic Core.
For genotyping, a~700 nt fragment of genomic DNA surrounding
the mTOR S2159 locus was PCR amplified and digested with SmaI.
The following PCR primers were used for genotyping: Forward: 50-
CTTCGTGACCCTCTCCTATCT-30; reverse: 50-AAGCCTGGGACCTCT
ACTATC-30.
Image editing
Adobe Photoshop was used for image preparation using levels, bright-
ness, and contrast equivalently over the entire image. Thin dotted
lines on images indicate where irrelevant lanes were excised and
flanking lanes juxtaposed from the same image at the same exposure.
Statistical analysis
Results are presented as mean  SD (or  SEM, where indicated)
or as 95% confidence intervals. Significance of the difference
between two measurements was determined by paired or unpaired
Student’s t-test (two-tailed or one-tailed, where indicated). Statisti-
cal test used and P-values are cited in the figure legends.
Expanded View for this article is available online.
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